Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres

Journal of Immunotherapy

Volumn 30, Issue 8, 2007, Pages 808-816

  Sabel, Michael S ^a,c   Arora, Alisha ^a   Su, Gang ^a   Griffith, Kent A ^a   Mathiowitz, Edith ^b   Reineke, Joshua J ^b   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BROWN UNIVERSITY   (United States)

^c Brown University ^*  (United States)

Author keywords

Immunotherapy; Interleukin 12; Interleukin 18; Intratumoral

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 18 BINDING PROTEIN; MICROSPHERE; POLYLACTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOTHERAPY; LUNG METASTASIS; LYMPH NODE; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DRUG THERAPY, COMBINATION; FEMALE; INJECTIONS, INTRALESIONAL; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; KILLER CELLS, NATURAL; LACTIC ACID; LUNG NEOPLASMS; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOCAPSULES; POLYMERS; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37349056065     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318156e6a7     Document Type: Article

References (44)

1. Crittenden MR, Thanarajasingam U, Vile RG, et al. Intratumoral immunotherapy: using the tumour against itself. Immunology. 2005;114:11-22.
2. Addison CL, Bramson JL, Hitt MM, et al. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 1998;5:1400-1409.
3. Gambotto A, Tuting T, McVey DL, et al. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Therapy. 1999;6:45-53.
4. Nasu Y, Bangma CH, Hull GW, et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastses in an orthotopic model. Gene Ther. 1999;6:338-349.
5. Kianmanesh A, Hackett NR, Lee JM, et al. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Human Gene Ther. 2001;12:2035-2049.
6. Liu Y, Ehtesham M, Samoto K, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. 2002;9:9-15.
7. Mastrangelo MJ, Lattime EC. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. 2002;9:1013-1021.
8. Yang AS, Monken CE, Lattime EC. Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte-macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res. 2003;63:6956-6961.
9. Heinzerling L, Dummer R, Pavlovic J, et al. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp Dermatol. 2002;11:232-240.
10. Schultz J, Heinzerling L, Pavlovic J, et al. Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. Cancer Gene Ther. 2000;12:1557-1565.
11. Tanigawa K, Yu H, Sun R, et al. Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother. 2000;48:635-643.
12. Hanna E, Zhang X, Woodlis J, et al. Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther. 2001;8:151-157.
13. Heinzerling LM, Feige K, Rieder S, et al. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med. 2001;78:692-702.
14. Nishioka Y, Hirao M, Robbins PD, et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin-12. Cancer Res. 1999;59:4035-4041.
15. Sharma S, Yang SC, Batra RK, et al. Intratumoral therapy with cytokine gene-modified dendritic cells in murine lung cancer models. Methods Mol Med. 2003;75:711-722.
16. Tahara H, Zitvogel L, Storkus WJ, et al. Antitumor effects in patients with melanoma, head and neck and breast cancer in a phase I/II clinical trial of IL-12 gene therapy. Proc Am Soc Clin Oncol. 1997;16:439a.
17. Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol. 2005;23:999-1010.
18. Egilmez NK, Jong YS, Iwanuma Y, et al. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunol Immunother. 1998;46:21-24.
19. Sabel MS, Hill H, Jong YS, et al. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery. 2001;130:470-478.
20. Hill HC, Conway TF Jr, Sabel MS, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 2002;62:7254-7263.
21. Sabel MS, Arora A, Su G, et al. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ T-cells and NK cells. Surgery. 2007. In press.
22. Sabel MS, Skitzki J, Stoolman L, et al. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol. 2004;11:147-156.
23. Arora A, Su G, Mathiowitz E, et al. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity. J Surg Oncol. 2006;94:403-412.
24. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T-cells. Nature. 1995;378:88-91.
25. Kohno K, Kataoka J, Ohtsuki T, et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol. 1997;158:1541-1550.
26. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol. 1979;97:587-600.
27. + tumor-draining lymph node cells involved in mediating tumor regression. J Leukocyte Biol. 1997;61:1-10.
28. Ito F, Li Q, Shreiner AB, et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell based vaccines. Cancer Res. 2004;64:8411-8419.
29. Micallef MJ, Ohtsuki T, Kohno K, et al. Interferon-gamma inducing factor enhances Th1 cytokine production by stimulated human T cells: synergism with interleukin 12 for interferon gamma production. Eur J Immunol. 1996;26:1647-1651.
30. Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human interferon gamma inducing factor (IGIF), expression in E. coli, and studies on the biologic activities of the protein. J Immunol. 1996;156:4274-4279.
31. Tatsumi T, Huang J, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003;63:6378-6386.
32. Baxevanis CN, Gritzapis AD, Papamichail M. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18. J Immunol. 2003;171:2953-2959.
33. Son Y, Kallal RM, Mailliard RB, et al. Interleukin 18 synergizes with IL-2 to enhance cytotoxicity, interferon gamma production, and expansion of natural killer cells. Cancer Res. 2001;61:884-888.
34. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest. 1998;101:1441-1452.
35. Osaki T, Peron J-M, Cai Q, et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma and IL-12 independent antitumor effects. J Immunol. 1998;160:1742-1749.
36. Yamanaka K, Hara I, Nagai H, et al. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18. Cancer Immunol Immunother. 1999;48:297-302.
37. Osaki T, Hashimoto W, Gambotto A, et al. Potent antitumor effects mediated by local expression of the mature form of the interferongamma inducing factor, interleukin-18. Gene Ther. 1999;6:808-815.
38. Nagai H, Hara I, Torikawa T, et al. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest. 2000;18:206-213.
39. Kishida T, Asada H, Satoh E, et al. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. 2001;8:1234-1240.
40. Li Q, Carr AL, Donald EJ, et al. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res. 2005;65:1063-1070.
41. Iinuma H, Okinaga K, Fukushima R, et al. Superior protective and therapeutic effects of IL-12 and IL-18 gene transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J Immunol. 2006;176:3461-3469.
42. Ino Y, Saeki Y, Fukuhara H, et al. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18 or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res. 2006;12:643-652.
43. Subleski JJ, Hall VL, Back TC, et al. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res. 2006;66:11005-11012.
44. Egilmez NK, Jong YS, Sabel MS, et al. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000;60:3832-3837.